Skip to Content

Vectibix (panitumumab) Disease Interactions

There are 5 disease interactions with Vectibix (panitumumab):


Egfr Inhibitors (Includes Vectibix) ↔ Cv/Electrolyte Imbalance

Severe Potential Hazard, Moderate plausibility

Applies to: Cardiovascular Disease, Electrolyte Abnormalities, Hypokalemia, Hypocalcemia, Heart Disease, Magnesium Imbalance

The use of certain EGFR inhibitors has been associated with progressive decreases in serum magnesium levels leading to severe cases of hypomagnesemia and accompanying electrolyte abnormalities, including hypocalcemia, and hypokalemia. The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of these agents. Periodically monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia, during and for at least 8 weeks following the completion of therapy. Caution is recommended when using these agents in patients predisposed to electrolyte imbalances and those with a history of coronary artery disease, congestive heart failure, or arrhythmias. Replete magnesium and other electrolytes as appropriate.


Egfr Inhibitors (Includes Vectibix) ↔ Dermatologic Toxicities

Severe Potential Hazard, Moderate plausibility

Applies to: Dermatitis - Drug-Induced

Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors. Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae. It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications. Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.


Egfr Inhibitors (Includes Vectibix) ↔ Ocular Disorders

Severe Potential Hazard, Moderate plausibility

Applies to: Ocular Infection

Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis. It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.


Egfr Inhibitors (Includes Vectibix) ↔ Pulmonary Toxicity

Severe Potential Hazard, Moderate plausibility

Applies to: Pulmonary Impairment, Fever

The use of certain EGFR inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.


Panitumumab (Includes Vectibix) ↔ Liver/Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Renal Dysfunction

No formal pharmacokinetic studies of panitumumab have been conducted in patients with renal or hepatic impairment. Close monitoring is recommended.

Vectibix (panitumumab) drug Interactions

There are 27 drug interactions with Vectibix (panitumumab)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.